Background: A serious long-term complication of drug-eluting stents (DES) is the occurrence of very late stent thrombosis (VLST) beyond one year after implantation. While VLST has been observed at least 3 to 5 years following the initial procedure, it remains unknown whether DES thrombosis is a finite phenomenon which abates over time or is a risk that persists indefinitely. Methods: A retrospective chart and angiographic review was performed to identify a series of patients who presented to our institution with acute myocardial infarction (MI) due to "very", very late stent thrombosis (VVLST), defined as stent thrombosis occurring more than 5 years after DES implantation. Results: The study group consisted of 6 patients (5 men and 1 woman), aged 32 to 70 years, who had angiographically confirmed definite VVLST. Five of the patients were active smokers and 3 were diabetic. Interval between stent implantation and VVLST ranged from 5.6 to 7.0 years. The DES was sirolimus-eluting in 3 patients and paclitaxel-eluting in 3 patients. None of the patients were taking clopidogrel at the time of VVLST. The interval between clopidogrel discontinuation and VVLST was 1 week in 2 patients, 3-6 months in 2 patients, and greater than 5 years in 2 patients. Only 2 patients were taking chronic aspirin therapy. Therefore, 4 of the 6 patients were on no antiplatelet therapy prior to VVLST. The clinical presentation of VVLST was an acute MI in all patients, with ST segment elevation in 5 of the 6. All patients were treated successfully by emergent repeat percutaneous coronary intervention. Conclusion: Risk of stent thrombosis persists beyond 5 years after implantation of first generation DES. These sobering findings underscore the need for clinical vigilance in these patients and corroborate current PCI guidelines which recommend continuing at least aspirin indefinitely after DES. The clinical significance of post-procedural hypotension has not been evaluated in patients with ST elevation myocardial infarction (STEMI) after successful primary percutaneous coronary intervention (PCI).
Background: A serious long-term complication of drug-eluting stents (DES) is the occurrence of very late stent thrombosis (VLST) beyond one year after implantation. While VLST has been observed at least 3 to 5 years following the initial procedure, it remains unknown whether DES thrombosis is a finite phenomenon which abates over time or is a risk that persists indefinitely. Methods: A retrospective chart and angiographic review was performed to identify a series of patients who presented to our institution with acute myocardial infarction (MI) due to "very", very late stent thrombosis (VVLST), defined as stent thrombosis occurring more than 5 years after DES implantation. Results: The study group consisted of 6 patients (5 men and 1 woman), aged 32 to 70 years, who had angiographically confirmed definite VVLST. Five of the patients were active smokers and 3 were diabetic. Interval between stent implantation and VVLST ranged from 5.6 to 7.0 years. The DES was sirolimus-eluting in 3 patients and paclitaxel-eluting in 3 patients. None of the patients were taking clopidogrel at the time of VVLST. The interval between clopidogrel discontinuation and VVLST was 1 week in 2 patients, 3-6 months in 2 patients, and greater than 5 years in 2 patients. Only 2 patients were taking chronic aspirin therapy. Therefore, 4 of the 6 patients were on no antiplatelet therapy prior to VVLST. The clinical presentation of VVLST was an acute MI in all patients, with ST segment elevation in 5 of the 6. All patients were treated successfully by emergent repeat percutaneous coronary intervention. Conclusion: Risk of stent thrombosis persists beyond 5 years after implantation of first generation DES. These sobering findings underscore the need for clinical vigilance in these patients and corroborate current PCI guidelines which recommend continuing at least aspirin indefinitely after DES. Methods: Total of 236pts with STEMI who underwent primary PCI were reviewed. Pts who presented with cardiogenic shock before or during PCI were excluded. Echocardiography was done within 48hrs. All pts underwent VH-IVUS imaging of culprit lesion.
Results: Among 236pts, 54pts presented with post-procedural hypotension after successful primary PCI without any definite cause. Pt age was 62 AE 8 yrs in post-PCI hypotensive STEMI vs 58 AE 13 in normotensive STEMI (p¼0.048). The incidence of hypertension was 41% (21/54) in post-PCI hypotensive STEMI vs 54% (98/182) in normotensive STEMI (p¼0.105). Peak troponin-I and CK-MB were similar, and Thrombolysis in myocardial infarction (TIMI) grade before PCI was lower in hypotensive group. However, door to balloon and symptom to balloon time were longer in hypotensive group. Ejection fraction was lower and left ventricular end-systolic dimension was larger in hypotensive group. Minimal lumen area (MLA) was smaller and maximal necrotic core (%) was larger in post-PCI hypotensive STEMI, but the incidence of VH-TCFA was similar (56% vs 42%, p¼0.505). By logistic multivariate regression analysis, the most important independent predictors of post-procedural hypotension were longer symptom to balloon time (OR 1.012, p¼0.0093) and percent maximal necrotic core (OR 1.244, p¼0.018). However, there were no significant differences in the 30days and 1yr MACCE of these two group. Conclusion: Post-procedural hypotension after successful primary PCI was predicted by delayed reperfusion time and prominent necrotic core of culprit lesion, although it results in no difference of patient's outcome. Background: The current treatment of ST segment elevation myocardial infarction (STEMI) is mechanical reperfusion by Primary Percutaneous Coronary Intervention (PPCI) or systemic thrombolysis. Several factors are related to non-reperfusion, with advanced age being particularly significant. At present, no study has examined the presentation and characteristics of the non-reperfused patient in Ireland. Further study is clearly needed in this area, especially as the older demographic of the population increases.
Objective: To define, understand and critically evaluate STEMI patients who do not receive reperfusion therapy. Methods: The Coronary Heart Attack Ireland Register (CHAIR) was used to identify STEMI patients who did not receive reperfusion therapy between January 1st 2007 and December 31st 2011. A retrospective review of patient charts was performed at Cork University Hospital, Mercy University Hospital, South Infirmary Victoria University Hospital and Mallow General Hospital. The contribution of non-reperfusion to patient mortality was also examined in terms of 30-day mortality and 1-year mortality post STEMI. Results: 77 cases were included. Results indicate that most were female (n¼47, 61%) with a median age of 80.39 years. 54.5% (n¼42) had a past medical history of coronary heart disease with hypertension being the main risk factor (n¼43, 55.8%). 49% (n¼38) were considered independent in terms of ADLs. Patient mortality at 30 days post STEMI was 55.8%. This increased to 61% at 1 year. Conclusion: As the older demographic in our population increases, this patient cohort will become particularly significant. Mortality among these patients is high yet a significant number were considered independent in terms of ADLs. Prospective evaluation of this patient cohort needs to take place to monitor the effect of the introduction of the PPCI National Strategy in Ireland in 2012. Internationally, larger studies are needed to determine the role of social factors as predictors of non-reperfusion.
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Predictors (OR, 3.59; 95% CI, p¼0.002) , and history of atrial fibrillation (OR, 3.47; 95% CI, 1.19-10.12; p¼0.02). Conclusions: Multiple patient-level characteristics were associated with IA of the cardiac catheterization laboratory. Younger age, absence of both chest pain and shortness of breath, recent cocaine use, and history of heart failure and atrial fibrillation were independent predictors of IA.
